Physician profile
William H Ayers
NPI 1851383368
$526.86
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $75.53 · 2021: $45.34 · 2022: $27.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $192.13 | 2019-2020 | |
| Davol INC. | $78.59 | 2019-2022 | |
| Eisai INC. | $77.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $34.47 | 2019 | |
| Puma Biotechnology, INC. | $29.25 | 2019 | |
| Braintree Laboratories, INC. | $23.84 | 2021 | |
| Daiichi Sankyo INC. | $22.56 | 2020 | |
| Innocoll Pharmaceuticals Limited | $21.50 | 2021 | |
| Merck Sharp & Dohme LLC | $17.76 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.95 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $12.17 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.